In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback